Pain Therapeutics (PTIE) Releases Quarterly Earnings Results
Pain Therapeutics (NASDAQ:PTIE) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, Bloomberg Earnings reports.
A number of research firms recently issued reports on PTIE. Zacks Investment Research downgraded Pain Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, September 19th. Gabelli downgraded Pain Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, July 17th.
About Pain Therapeutics
Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.
Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.